International Stem Cell Corporation Obtains Exclusive Rights in the US and Canada to Distribute Approved Human Skin Model for Toxicity Testing

International Stem Cell Corporation (OTCBB: ISCO) announced today that it has entered into an exclusive agreement with CellSystems Biotechnologie to distribute laboratory-cultured models of human skin useful for testing the hazardous properties of consumer products and for dermatological and pharmaceutical research. Such testing is likely to be soon required for certain types of consumer products sold into the European Union.

According to International Stem Cell’s (ISCO) President Jeffrey Janus, “This agreement is another positive step in ISCO’s strategic plan to become the primary source of high quality human cells for the therapeutic and research markets by leveraging its manufacturing and distribution resources.”

ISCO is the first company to develop a unique type of human stem cell line that promises to eliminate the immune rejection problems that plague cell-transplantation therapies and opens the potential to create the first true “Stem Cell Bank.” ISCO’s technology, called parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs – a fact that alleviates many ethical issues.

ISCO’s human cell and cell culture research products are manufactured and distributed under the “Lifeline” brand by wholly-owned subsidiary Lifeline Cell Technology, LLC, based in Walkersville, Maryland (www.lifelinecelltech.com).

The laboratory-cultured models of human skin, called EST-1000 and AST-2000 were developed by CellSystems and contain cells manufactured by Lifeline. These three-dimensional skin cell models are used as alternative methods to animal testing in the field of Skin Corrosion, Skin Irritation, Skin Sensitization, Genotoxicity and Phototoxicity.

“We have worked with the Lifeline staff and know their abilities to provide excellent customer service and their ability to consistently produce high quality products; a critical factor for researchers that depend on human cells for the success of their research,” said Horst W. Fuchs, President of CellSystems Biotechnologie. “This agreement between our companies opens a distribution channel for CellSystems’ skin model products to scientific researchers throughout the United States and Canada.”

“While the sale of these Lifeline stem cell and research products provides ISCO immediate cash flow, it also helps embed ISCO’s products into successful therapeutic and quality control procedures worldwide, providing a revenue stream of shared royalties beyond traditional sales,” added Janus.

ABOUT CELLSYSTEMS:

CellSystems Biotechnologie Vertrieb GmbH, founded in Germany in 1992 as a sales and marketing organization, is one of the main providers of selected high quality and innovative cell culture products to the life sciences community. For more than fifteen years, CellSystems has provided the Life Science community with the most sophisticated cell biology products available. Their core competency in Human Primary Cells and adult Stem Cells has resulted in the development of three dimensional skin cell models which are used as alternative methods to animal testing in the field of Skin Corrosion, Skin Irritation, Skin Sensitization, Genotoxicity and Phototoxicity. CellSystems also provides cell models for Angionenesis, Blood-Brain-Barrier and Inhalation Toxicology. Visit the CellSystem’s web site at: www.cellsystems.biz.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true “Stem Cell Bank” and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

International Stem Cell Corporation Obtains Exclusive Rights in the US and Canada to Distribute Approved Human Skin Model for Toxicity Testing

International Stem Cell Corporation (OTCBB: ISCO) announced today that it has entered into an exclusive agreement with CellSystems Biotechnologie to distribute laboratory-cultured models of human skin useful for testing the hazardous properties of consumer products and for dermatological and pharmaceutical research. Such testing is likely to be soon required for certain types of consumer products sold into the European Union.

According to International Stem Cell’s (ISCO) President Jeffrey Janus, “This agreement is another positive step in ISCO’s strategic plan to become the primary source of high quality human cells for the therapeutic and research markets by leveraging its manufacturing and distribution resources.”

ISCO is the first company to develop a unique type of human stem cell line that promises to eliminate the immune rejection problems that plague cell-transplantation therapies and opens the potential to create the first true “Stem Cell Bank.” ISCO’s technology, called parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs – a fact that alleviates many ethical issues.

ISCO’s human cell and cell culture research products are manufactured and distributed under the “Lifeline” brand by wholly-owned subsidiary Lifeline Cell Technology, LLC, based in Walkersville, Maryland (www.lifelinecelltech.com).

The laboratory-cultured models of human skin, called EST-1000 and AST-2000 were developed by CellSystems and contain cells manufactured by Lifeline. These three-dimensional skin cell models are used as alternative methods to animal testing in the field of Skin Corrosion, Skin Irritation, Skin Sensitization, Genotoxicity and Phototoxicity.

“We have worked with the Lifeline staff and know their abilities to provide excellent customer service and their ability to consistently produce high quality products; a critical factor for researchers that depend on human cells for the success of their research,” said Horst W. Fuchs, President of CellSystems Biotechnologie. “This agreement between our companies opens a distribution channel for CellSystems’ skin model products to scientific researchers throughout the United States and Canada.”

“While the sale of these Lifeline stem cell and research products provides ISCO immediate cash flow, it also helps embed ISCO’s products into successful therapeutic and quality control procedures worldwide, providing a revenue stream of shared royalties beyond traditional sales,” added Janus.

ABOUT CELLSYSTEMS:

CellSystems Biotechnologie Vertrieb GmbH, founded in Germany in 1992 as a sales and marketing organization, is one of the main providers of selected high quality and innovative cell culture products to the life sciences community. For more than fifteen years, CellSystems has provided the Life Science community with the most sophisticated cell biology products available. Their core competency in Human Primary Cells and adult Stem Cells has resulted in the development of three dimensional skin cell models which are used as alternative methods to animal testing in the field of Skin Corrosion, Skin Irritation, Skin Sensitization, Genotoxicity and Phototoxicity. CellSystems also provides cell models for Angionenesis, Blood-Brain-Barrier and Inhalation Toxicology. Visit the CellSystem’s web site at: www.cellsystems.biz.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true “Stem Cell Bank” and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

International Stem Cell Corporation Announces Collaboration with the University of Cambridge to Study Parthenogenetic Stem Cells

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO), announced today a new collaboration with the University of Cambridge (UK) as part of ISCO’s ongoing strategy to work with scientific leaders across the world to expand the scientific data relating to parthenogenetic stem cells.

According to Roger A. Pedersen, PhD, Professor of Regenerative Medicine at Cambridge Institute for Medical Research, “We look forward to conducting molecular and genetic assessment of imprinted gene expression and DNA methylation on these unique cells.”

ISCO is the first company in the world to perfect a process for creating human stem cells from unfertilized eggs. These cells are called “parthenogenetic” stem cells and they alleviate two critical problems inherent to the use of embryonic stem cells for cell transplantation, immune rejection and ethical issues associated with the use of fertilized human embryos. Such cells can be “matched” to the immune systems of millions of persons. ISCO’s goal is to create a “cell bank” of clinical grade parthenogenetic cells available for immediate use without having to isolate cells from the patient’s own body or depend on cells isolated from other living individuals.

“Collaborations with leading researchers such as Dr. Pedersen at the University of Cambridge brings us closer to ISCO’s goal of creating a true stem cell bank that could offer on-demand delivery of stem cells matched to a patient’s own immune system,” said Jeffrey Janus, president of International Stem Cell Corporation. “Our intent is to provide these HLA-homozygous cell lines to researchers across the world to advance the field of regenerative medicine, as well as to commercialize our cells for cell transplant therapies.”

ISCO’s discovery of a way to make parthenogenetic cells that match the immune system of millions of persons was first announced in December, 2007 in a peer reviewed paper authored by ISCO’s Chief Scientific Officer, Dr. Elena Revazova, MD, PhD, entitled “HLA Homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts,” published in the online edition of Cloning and Stem Cells Journal: http://www.liebertonline.com/doi/pdfplus/10.1089/clo.2007.0063. One such line, identified as hpSC-Hhom-4, was found to match the most common immune type found across the United States, opening the door to potential therapeutic application for tens of millions of people of different races, sexes and ages.

About University of Cambridge:

As the University of Cambridge approaches its eight-hundredth anniversary in 2009, it is looking to the future. Its mission is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. It admits the very best and brightest students, regardless of background, and offers one of the UK’s most generous bursary schemes.

The University of Cambridge’s reputation for excellence is known internationally and reflects the scholastic achievements of its academics and students, as well as the world-class original research carried out by its staff. Some of the most significant scientific breakthroughs occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history’s greatest minds and has produced more Nobel Prize winners than any other UK institution with over 80 laureates.

About International Stem Cell Corporation:

International Stem Cell Corporation (ISCO) is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists also have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true “Stem Cell Bank” and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.